Published on September 29, 2024 at 7:48 p.m. / Modified on September 29, 2024 at 7:50 p.m.
Almost a year ago, Sandoz separated from Novartis and entered the Swiss stock exchange. In 1996, its name merged with the Basel pharmaceutical giant when it merged with Ciba-Geigy. Created at the end of the 19th century, the company, which marked Swiss industrial history, has therefore regained its independence in a sector under pressure, that of generic and biosimilar medicines.
At the end of the first half of 2024, Sandoz posted a turnover up 6% compared to the same period in 2023 at 5.05 billion dollars (4.30 billion francs) with a basic net profit down 18% to 484 million. When presenting its first annual figures for 2023, it had already seen its profitability decline. Its president, Gilbert Ghostine, draws an initial assessment of this past year and identifies the challenges facing Sandoz, between shortages of basic treatments and pressure on prices.
Want to read all of our articles?
For CHF 29.- per month, enjoy unlimited access to our articles, without obligation!
I subscribe
Good reasons to subscribe to Le Temps:
- Unlimited access to all content available on the website.
- Unlimited access to all content available on the mobile application
- Sharing plan of 5 articles per month
- Consultation of the digital version of the newspaper from 10 p.m. the day before
- Access to supplements and T, the Temps magazine, in e-paper format
- Access to a set of exclusive benefits reserved for subscribers
Already a subscriber?
Log in
